New Line Medicines Profile
Key Indicators
- Authorised Capital ₹ 6.00 M
- Paid Up Capital ₹ 3.10 M
- Company Age 8 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
About New Line Medicines
New Line Medicines Private Limited (NLMPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 March 2016 (Eight years and ten months 14 days old ). Its registered office is in Guntur, Andhra Pradesh, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 6.00 M and a paid-up capital of Rs 3.10 M, as per Ministry of Corporate Affairs (MCA) records.
Komala Vankayalapati and Srinivasa Vankayalapati serve as directors at the Company.
Company Details
-
Location
Guntur, Andhra Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24100AP2016PTC098568
-
Company No.
098568
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
19 Mar 2016
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Vijayawada
Industry
Who are the key members and board of directors at New Line Medicines?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Komala Vankayalapati
|
Director | 19-Mar-2016 | Current |
|
Srinivasa Vankayalapati
|
Director | 19-Mar-2016 | Current |
Financial Performance of New Line Medicines.
New Line Medicines Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of New Line Medicines?
Unlock access to New Line Medicines's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Arrien-Rajendra Spinning Mills Private LimitedKomala Vankayalapati and Srinivasa Vankayalapati are mutual person
-
Unitygrowth Investments Private Limited
Komala Vankayalapati and Srinivasa Vankayalapati are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at New Line Medicines?
Unlock and access historical data on people associated with New Line Medicines, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of New Line Medicines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped New Line Medicines's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.